A clinical study to evaluate the safety and preliminary efficacy of BPS804 in adults with hypophosphatasia A clinical study to evaluate the safety and preliminary efficacy of BPS804 in adults with hypophosph ...
An open-label, intra-patient dose-escalation study to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of multiple infusions of BPS804 in adults with hypophosphatasia An open-label, intra-patient dose-escalation study to evaluate the safety and tolerability, pharmaco ...
Hypophosphatasia (HPP) is a rare genetic metabolic disorder which results in impaired skeletal mineralization, and which is caused by the absence of or by deficient enzymatic activity of the tissue-nonspecific alkaline phosphatase (TNSALP) MedDRA version: 14.1;Level: PT;Classification code 10049933;Term: Hypophosphatasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Hypophosphatasia (HPP) is a rare genetic metabolic disorder which results in impaired skeletal miner ...